| 臺大學術典藏 |
2021-03-29T06:08:22Z |
Comparison of DNA stabilizers and storage conditions on preserving fecal microbiota profiles
|
Chen, C.-C.; Wu, W.-K.; Chang, C.-M.; Panyod, S.; Lu, T.-P.; Liou, J.-M.; Fang, Y.-J.; Chuang, E.Y.; Wu, M.-S.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2021-03-29T06:08:21Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou, J.-M.; Chen, C.-C.; Chang, C.-M.; Fang, Y.-J.; Bair, M.-J.; Chen, P.-Y.; Chang, C.-Y.; Hsu, Y.-C.; Chen, M.-J.; Chen, C.-C.; Lee, J.-Y.; Yang, T.-H.; Luo, J.-C.; Chen, C.-Y.; Hsu, W.-F.; Chen, Y.-N.; Wu, J.-Y.; Lin, J.-T.; Lu, T.-P.; Chuang, E.Y.; El-Omar, E.M.; Wu, M.-S.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2021-03-18T02:02:50Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.;Chen C.-C.;Chang C.-Y.;Chen M.-J.;Fang Y.-J.;Lee J.-Y.;Chen C.-C.;Hsu S.-J.;Hsu Y.-C.;Tseng C.-H.;Tseng P.-H.;Chang L.;Chang W.-H.;Wang H.-P.;Chia-Tung Shun;Wu J.-Y.;Lee Y.-C.;Lin J.-T.;Wu M.-S.;Lin C.-H.;Chow L.-P.;Cheng T.-Y.;Wu C.-Y.;Lee Ching-Tai C.-T, Wang W.-L.;Tai C.-M.;Wang Y.-C.;Wang C.-H.;Kuo S.-H.;Wu C.-Y.; Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; CHIA-TUNG SHUN; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-03-18T02:02:50Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.;Chen C.-C.;Chen M.-J.;Chen C.-C.;Chang C.-Y.;Fang Y.-J.;Lee J.-Y.;Hsu S.-J.;Luo J.-C.;Chang W.-H.;Hsu Y.-C.;Tseng C.-H.;Tseng P.-H.;Wang H.-P.;Yang U.-C.;Chia-Tung Shun;Lin J.-T.;Lee Y.-C.;Wu M.-S.; Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; CHIA-TUNG SHUN; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2021-03-18T02:02:40Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; CHIA-TUNG SHUN; Wu M.-S. |
| 臺大學術典藏 |
2021-03-18T02:02:38Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; CHIA-TUNG SHUN; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2021-03-18T02:02:35Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; CHIA-TUNG SHUN; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease and Helicobacter Consortium |
| 臺大學術典藏 |
2021-03-18T02:02:34Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; CHIA-TUNG SHUN; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease and Helicobacter Consortium |
| 臺大學術典藏 |
2021-03-18T02:02:26Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.;Chen C.-C.;Fang Y.-J.;Chen P.-Y.;Chang C.-Y.;Chou C.-K.;Chen M.-J.;Tseng C.-H.;Lee J.-Y.;Yang T.-H.;Chiu M.-C.;Yu J.-J.;Kuo C.-C.;Luo J.-C.;Hsu W.-F.;Hu W.-H.;Tsai M.-H.;Lin J.-T.;Chia-Tung Shun;Twu G.;Lee Y.-C.;Bair M.-J.;Wu M.-S.;Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; CHIA-TUNG SHUN; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease and Helicobacter Consortium |
| 臺大學術典藏 |
2021-03-18T02:02:25Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.;Chen P.-Y.;Luo J.-C.;Lee J.-Y.;Chen C.-C.;Fang Y.-J.;Yang T.-H.;Chang C.-Y.;Bair M.-J.;Chen M.-J.;Hsu Y.-C.;Hsu W.-F.;Chang C.-C.;Lin J.-T.;Chia-Tung Shun;El-Omar E.M.;Wu M.-S.;Liou J.-M.;Lee Y.-C.;Lin J.-T.;Wu C.-Y.;Wu J.-Y.;Chen C.-C.;Lin C.-H.;Fang Y.-R.;Bair M.-J.;Luo J.-C.;Cheng T.-Y.;Tseng P.-H.;Chiu H.-M.;Chang C.-C.;Yu C.-C.;Chiu M.-C.;Chen Y.-N.;Hu W.-H.;Chou C.-K.;Tai C.-M.;Lee C.-T.;Wang W.-L.;Chang W.-S.;Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; CHIA-TUNG SHUN; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease and Helicobacter Consortium |
| 臺大學術典藏 |
2021-03-18T02:02:20Z |
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trial
|
Chen C.-C.;Luo J.-C.;Fang Y.-J.;Lee J.-Y.;Kuo C.-C.;Yang T.-H.;Chiu M.-C.;Yu J.-J.;Bair M.-J.;Chen P.-Y.;Chou C.-K.;Chen C.-Y.;Chang C.-Y.;Hsu Y.-C.;Tseng C.-H.;Hsu W.-F.;Hu W.-H.;Tsai M.-H.;Hsieh C.-L.;Chen M.-J.;Chia-Tung Shun;Liu T.-Y.;Lee§ Y.-C.;Liou§ J.-M.;Wu§ M.-S.;And For The Taiwan Gastrointestinal Disease;Helicobacter Consortium; Chen C.-C.; Luo J.-C.; Fang Y.-J.; Lee J.-Y.; Kuo C.-C.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Bair M.-J.; Chen P.-Y.; Chou C.-K.; Chen C.-Y.; Chang C.-Y.; Hsu Y.-C.; Tseng C.-H.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Hsieh C.-L.; Chen M.-J.; CHIA-TUNG SHUN; Liu T.-Y.; Lee§ Y.-C.; Liou§ J.-M.; Wu§ M.-S.; and for the Taiwan Gastrointestinal Disease and Helicobacter Consortium |
| 臺大學術典藏 |
2021-03-10T07:09:14Z |
Suggested cutoff tumor size for management of small EUS-suspected gastric gastrointestinal stromal tumors
|
Fang Y.-J.; TSU-YAO CHENG; Sun M.-S.; Yang C.-S.; Chen J.-H.; Liao W.-C.; Wang H.-P. |
| 臺大學術典藏 |
2021-03-10T07:09:13Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; TSU-YAO CHENG; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-03-10T07:09:08Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.;Chen P.-Y.;Luo J.-C.;Lee J.-Y.;Chen C.-C.;Fang Y.-J.;Yang T.-H.;Chang C.-Y.;Bair M.-J.;Chen M.-J.;Hsu Y.-C.;Hsu W.-F.;Chang C.-C.;Lin J.-T.;Shun C.-T.;El-Omar E.M.;Wu M.-S.;Liou J.-M.;Lee Y.-C.;Lin J.-T.;Wu C.-Y.;Wu J.-Y.;Chen C.-C.;Lin C.-H.;Fang Y.-R.;Bair M.-J.;Luo J.-C.;Tsu-Yao Cheng;Tseng P.-H.;Chiu H.-M.;Chang C.-C.;Yu C.-C.;Chiu M.-C.;Chen Y.-N.;Hu W.-H.;Chou C.-K.;Tai C.-M.;Lee C.-T.;Wang W.-L.;Chang W.-S.;Taiwan Gastrointestinal Disease;Helicobacter Consortium; Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; TSU-YAO CHENG; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease and Helicobacter Consortium |
| 臺大學術典藏 |
2021-03-09T01:43:25Z |
Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Fang Y.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:16Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; TUNG-HUNG SU; Liu C.-J.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:09Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; TUNG-HUNG SU; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-05T08:19:38Z |
Computer-generated surface and tone enhancements to distinguish neoplastic from non-neoplastic colon polyps less than 1 cm in diameter
|
Han M.-L.; Lee Y.-C.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Lin T.-L.; Lin L.-W.; PING-HUEI TSENG; Wu M.-S.; Wang H.-P. |
| 臺大學術典藏 |
2021-03-05T08:19:38Z |
Randomised clinical trial: High-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
|
Chen C.-C.; Lee J.-Y.; Fang Y.-J.; Hsu S.-J.; Han M.-L.; PING-HUEI TSENG; Liou J.-M.; Hu F.-C.; Lin T.-L.; Wu M.-S.; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2021-03-05T08:19:37Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; PING-HUEI TSENG; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-03-05T08:19:37Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; PING-HUEI TSENG; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2021-03-05T08:19:30Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; PING-HUEI TSENG; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2021-03-05T08:19:25Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; PING-HUEI TSENG; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-26T02:00:03Z |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; WANG-HUEI SHENG; Wang H.-P.; Wu M.-S.; Lin J.-T. |
| 臺大學術典藏 |
2021-02-23T08:26:32Z |
Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma
|
Yang S.-H.; Lin L.-W.; Fang Y.-J.; Cheng A.-L.; SUNG-HSIN KUO |
